Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 P-fimbriae vaccines. I. Cross reactive antibodies to heterologous P-fimbriae.

Literature DB >> 2577146

P-fimbriae vaccines. I. Cross reactive antibodies to heterologous P-fimbriae.

M B Kaack¹, A Pere, T K Korhonen, S B Svenson, J A Roberts.

Abstract

To test for cross-protective capacity of two different P-fimbriae vaccines we vaccinated baboons with fimbriae purified from either Escherichia coli strain ER2 or strain JR1. The vaccinated animals showed elevated antibody titers to P-fimbriae from each of the E. coli strains used, suggesting cross-reactivity as was expected from the results of immunoprecipitation of the fimbriae. Enzyme-linked immunosorbent assay inhibition by heterologous P-fimbriae proved this to be true immunologic cross-reactivity.

Entities: Species

Mesh：

Substances：

Year: 1989 PMID： 2577146 DOI： 10.1007/bf00850212

Source DB: PubMed Journal: Pediatr Nephrol ISSN： 0931-041X Impact factor: 3.714

27 in total

Review 1. Genetic study of piliation in Escherichia coli: implications for understanding microbe-host interactions at the molecular level.

Authors: P E Orndorff
Journal: Pathol Immunopathol Res Date: 1987

2. Experimental pyelonephritis in the monkey. VII. Ascending pyelonephritis in the absence of vesicoureteral reflux.

Authors: J A Roberts; G M Suarez; B Kaack; G Kallenius; S B Svenson
Journal: J Urol Date: 1985-06 Impact factor: 7.450

3. Occurrence of type-1C fimbriae on Escherichia coli strains isolated from human extraintestinal infections.

Authors: A Pere; M Leinonen; V Väisänen-Rhen; M Rhen; T K Korhonen
Journal: J Gen Microbiol Date: 1985-07

4. P-antigen-recognizing fimbriae from human uropathogenic Escherichia coli strains.

Authors: T K Korhonen; V Väisänen; H Saxén; H Hultberg; S B Svenson
Journal: Infect Immun Date: 1982-07 Impact factor: 3.441

5. Expression of P, type-1, and type-1C fimbriae of Escherichia coli in the urine of patients with acute urinary tract infection.

Authors: A Pere; B Nowicki; H Saxén; A Siitonen; T K Korhonen
Journal: J Infect Dis Date: 1987-10 Impact factor: 5.226

6. Occurrence of P-fimbriated Escherichia coli in urinary tract infections.

Authors: G Källenius; R Möllby; S B Svenson; I Helin; H Hultberg; B Cedergren; J Winberg
Journal: Lancet Date: 1981 Dec 19-26 Impact factor: 79.321

7. New surface-associated heat-labile colonization factor antigen (CFA/II) produced by enterotoxigenic Escherichia coli of serogroups O6 and O8.

Authors: D G Evans; D J Evans
Journal: Infect Immun Date: 1978-08 Impact factor: 3.441

4. Prevention of renal scarring from pyelonephritis in nonhuman primates by vaccination with a synthetic Escherichia coli serotype O8 oligosaccharide-protein conjugate.

Authors: J A Roberts; M B Kaack; G Baskin; S B Svenson
Journal: Infect Immun Date: 1993-12 Impact factor: 3.441

4 in total

P-fimbriae vaccines. I. Cross reactive antibodies to heterologous P-fimbriae.

Review 1. Genetic study of piliation in Escherichia coli: implications for understanding microbe-host interactions at the molecular level.

2. Experimental pyelonephritis in the monkey. VII. Ascending pyelonephritis in the absence of vesicoureteral reflux.

3. Occurrence of type-1C fimbriae on Escherichia coli strains isolated from human extraintestinal infections.

4. P-antigen-recognizing fimbriae from human uropathogenic Escherichia coli strains.

5. Expression of P, type-1, and type-1C fimbriae of Escherichia coli in the urine of patients with acute urinary tract infection.

6. Occurrence of P-fimbriated Escherichia coli in urinary tract infections.

7. New surface-associated heat-labile colonization factor antigen (CFA/II) produced by enterotoxigenic Escherichia coli of serogroups O6 and O8.

8. Experimental pyelonephritis. V. Functional characteristics of pyelonephritis.

9. Maternal immunization with P fimbriae for the prevention of neonatal pyelonephritis.

10. Immunology of pyelonephritis in the primate model. V. Effect of superoxide dismutase.

1. Attenuation of antibody response to acute pyelonephritis by treatment with antibiotics.

2. P-fimbriae vaccines. II. Cross reactive protection against pyelonephritis.

3. Protective anti-idiotype antibodies in the primate model of pyelonephritis.

4. Prevention of renal scarring from pyelonephritis in nonhuman primates by vaccination with a synthetic Escherichia coli serotype O8 oligosaccharide-protein conjugate.